Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-CER-001 plaque penetration PET study in advanced atherosclerosis
NL-OMON40758Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2014
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label, single-arm trial of CER-001 in atherosclerosis and cardiac morbidity, sponsored by Amsterdam University Medical Center. Primary endpoint: Plaque CER-001 uptake over time by PET imaging. Started Jul 2014; status: active, not recruiting.
02
Drugs
CER-001
03
Conditions
atherosclerosiscardiac morbidity
Beyond the preview
Go deeper on NL-OMON40758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40758.